Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| U1111-1240-4039 | Other Identifier | World Health Organization (WHO) |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of the study is to collect information on how Rybelsus® works in people with type 2 diabetes and to see if Rybelsus® can lower their blood sugar levels. Participants will get Rybelsus® as prescribed to them by the study doctor. The study will last for about 8-10 months. Participants will be asked to complete a questionnaire about how they take their Rybelsus® tablets. Participants will complete this questionnaire during their normally scheduled visit with the study doctor.
Participants will be asked to complete some questionnaires about their diabetes treatment. Participants will complete these during normally scheduled visits with the study doctor.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients with type 2 diabetes | Adult patients with type 2 diabetes and naïve to injectable glucose-lowering treatment. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Oral Semaglutide | Drug | Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study. |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Glycated haemoglobin (HbA1c ) | Percent-points | From baseline (week 0) to End of Study visit (V3) (week 34-44) |
| Measure | Description | Time Frame |
|---|---|---|
| Relative change in body weight | Percent | From baseline (week 0) to End of Study visit (V3) (week 34-44) |
| Absolute change in body weight | Kilogram (Kg) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Adult patients with type 2 diabetes and naïve to injectable glucose-lowering treatment.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Clinical Transparency (dept. 1452) | Novo Nordisk A/S | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Master Centre for Sweden | Malmö | 202 15 | Sweden |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41986942 | Derived | Gonzalez-Galvez G, Garnica-Cuellar JC, Colin-Garcia MA, Ferreira-Hermosillo A, Jimenez-Ramos SA, Contreras-Sandoval AY, Cruz-Puente P, Duarte-Vega M. A Multicentre, Prospective, Non-Interventional Single-Arm Study Investigating the Impact of Once-Daily Oral Semaglutide in a Real-World Adult Population With Type 2 Diabetes in Mexico. Endocrinol Diabetes Metab. 2026 May;9(3):e70219. doi: 10.1002/edm2.70219. | |
| 39535683 |
Not provided
Not provided
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003924 | Diabetes Mellitus, Type 2 |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C000591245 | semaglutide |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| From baseline (week 0) to End of Study visit (V3) (week 34-44) |
| HbA1c <7% (Yes/No) | Percentage of patients achieving or not achieving the target value | End of Study visit (V3) (week 34-44) |
| HbA1c reduction >=1%-points and body weight reduction of >=5% (Yes/No) | Percentage of patients achieving or not achieving the reduction | From baseline (week 0) to End of Study visit (V3) (week 34-44) |
| HbA1c reduction >=1%-points and body weight reduction of >=3% (Yes/No) | Percentage of patients achieving or not achieving the reduction | From baseline (week 0) to End of Study visit (V3) (week 34-44) |
| Diabetes Treatment Satisfaction Questionnaire, change (DTSQc), relative treatment satisfaction | Total score | End of Study visit (V3) (week 34-44) |
| Diabetes Treatment Satisfaction Questionnaire, status (DTSQs), change in absolute treatment satisfaction | Total score | From baseline (week 0) to End of Study visit (V3) (week 34-44) |
| Derived |
| Rudofsky G, Amadid H, Braae UC, Catrina SB, Kick A, Mandavya K, Roslind K, Saravanan P, van Houtum W, Jain AB. Oral Semaglutide Use in Type 2 Diabetes: A Pooled Analysis of Clinical and Patient-Reported Outcomes from Seven PIONEER REAL Prospective Real-World Studies. Diabetes Ther. 2025 Jan;16(1):73-87. doi: 10.1007/s13300-024-01668-6. Epub 2024 Nov 13. |
| 39052163 | Derived | Catrina SB, Amadid H, Braae UC, Dereke J, Ekberg NR, Klanger B, Jansson S. PIONEER REAL Sweden: A Multicentre, Prospective, Real-World Observational Study of Oral Semaglutide Use in Adults with Type 2 Diabetes in Swedish Clinical Practice. Diabetes Ther. 2024 Sep;15(9):2079-2095. doi: 10.1007/s13300-024-01614-6. Epub 2024 Jul 25. |
| D004700 | Endocrine System Diseases |